Health

TRUMP TRIMS THE FAT: Weight-Loss Drug Prices Slashed in New Deals — 'A Triumph for American Patients' [WATCH]

posted by Hannity Staff - 11.06.25

President Donald Trump just scored a win for American wallets — and waistlines.

On Thursday, Trump announced major price-cutting deals with pharmaceutical giants Novo Nordisk and Eli Lilly to slash the cost of their wildly popular weight-loss drugs, making them more affordable for millions of Americans.

“A triumph for American patients that will save lives and improve the health of millions and millions of Americans,” Trump declared.

Under the deal, Novo Nordisk will lower the cost of its lowest-dose Wegovy injections to $149 per month, pending approval, and apply the discount across all its direct-to-patient products.

The company also confirmed that Wegovy and Ozempic will soon see reduced prices under Medicare Part D, Medicaid, and self-pay options — with full details expected in the coming weeks.

Meanwhile, Eli Lilly announced that Zepbound will start at $299 for the lowest dose and $449 for higher doses, roughly $50 less than current rates — and comparable to prices in Europe. The company’s upcoming oral obesity pill Orforglipron will also launch at $149 per month once approved.

For Medicare patients, Lilly promised no one will pay more than $50 a month for Zepbound or Orforglipron. Additional medications — including Emgality, Trulicity, and Mounjaro — are being added to LillyDirect at 50% to 60% off current list prices.

The drugs, part of the GLP-1 family, mimic natural hormones that regulate appetite and blood sugar — helping patients lose weight and manage diabetes.

Trump’s new deal marks another push to lower prescription costs and put pressure on Big Pharma, delivering a dose of relief for patients who’ve been paying a premium for pounds lost.

Watch the clips below:

Thank you for visiting Hannity.com. You are about to leave
Hannity.com and proceed to a site owned and operated by a third party.
Hannity.com has no control over the content of this third-party site.
Click OK to proceed.
OK
X
You may if you would no longer like to receive a newsletter.
You have been successfully unsubscribed!
Please see our Terms of Use and Privacy Notice .
If you have any questions or concerns please contact us.